AISR fortnightly report no. 14 – 26 September to 9 October 2022

The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons.


AISR fortnightly report no. 14 – 26 September to 9 October 2022

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
Health sector

The Australian Influenza Surveillance Report (AISR) is compiled from several data sources used to monitor influenza activity and severity in the community. These data sources include:

  • laboratory-confirmed notifications to NNDSS
  • influenza-associated hospitalisations
  • sentinel influenza-like illness (ILI) reporting from general practitioners
  • ILI-related community level surveys
  • sentinel laboratory testing results.

The AISR is published fortnightly during the influenza season, typically between May and October. Influenza activity updates may be published outside of the seasonal period.

Key messages

It is important to note that due to the COVID-19 epidemic in Australia, data reported from the various influenza surveillance systems may not represent an accurate reflection of influenza activity. Results should be interpreted with caution, especially where comparisons are made to previous influenza seasons. Interpretation of influenza activity data from April 2020 onwards should take into account, but are not limited to, the impact of social distancing measures, likely changes in health seeking behaviour of the community including access to alternative streams of acute respiratory infection specific health services, and focussed testing for COVID-19 response activities. For information on COVID-19 incidence, severity, and distribution in Australia, please refer to COVID-19 epidemiology reports.


Influenza-like-illness (ILI) activity in the community is low after activity peaked in June 2022.

Nationally, notifications of laboratory-confirmed influenza have continued to decrease in the past fortnight and remain lower than average for this time of year compared to previous years.


Clinical severity for the season to date, as measured through the proportion of patients admitted directly to ICU, and deaths attributed to influenza, is low.


The impact for the season to date, as measured through the rate of FluTracking respondents absent from normal duties and the number of sentinel hospital patients with influenza, is low to moderate.

At-risk populations

In 2022 to date, people aged 5–9 years, children aged younger than 5 years, and people aged 10–19 years have the highest notification rates.


To date, 82.7% of notifications of laboratory-confirmed influenza reported to the NNDSS were influenza A, of which 94.4% were influenza A(unsubtyped), 0.9% were influenza A(H1N1), and 4.7% were influenza A(H3N2). Influenza B accounted for 0.2% of notifications, less than 0.1% were A&B co-infections, and 17.1% were untyped.

Vaccine match and effectiveness

Of the 2,570 samples referred to the WHOCC to date, 92.4% of influenza A(H1N1), 94.5% of influenza A(H3N2), and the six influenza B/Victoria samples, were characterised as antigenically similar to the corresponding vaccine components.

Vaccine effectiveness is a measure of the protective effect of influenza vaccines against influenza and its complications and is typically around 40–60%. Based on preliminary estimates from sentinel hospitals (FluCAN), vaccine effectiveness appears at the lower end of the moderate range in 2022.

Help us improve

If you would like a response please use the enquiries form instead.